再鼎医药(09688)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09688 再鼎医药

未开盘 07-29 16:08:21

14.400

-0.550

-3.68%

最高14.870	最低14.300	成交量497.01万
今开14.870	昨收14.950	日振幅3.81%
总市值163.87亿	流通市值163.87亿	总股本11.38亿
成交额7,189万	换手率0.44%	流通股本11.38亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09688","market":"HK","secType":"STK","nameCN":"再鼎医药","latestPrice":14.4,"timestamp":1785312501008,"preClose":14.95,"halted":0,"volume":4970105,"delay":0,"changeRate":-0.03678929765886281,"floatShares":1138000000,"shares":1138000000,"eps":-1.2568779998117763,"marketStatus":"未开盘","change":-0.55,"latestTime":"07-29 16:08:21","open":14.87,"high":14.87,"low":14.3,"amount":71892084,"amplitude":0.038127,"askPrice":14.4,"askSize":7200,"bidPrice":14.38,"bidSize":2200,"shortable":3,"etf":0,"ttmEps":-1.2676537942717319,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785375000000},"marketStatusCode":0,"adr":0,"listingDate":1601222400000,"exchange":"SEHK","adjPreClose":14.95,"openAndCloseTimeList":[[1785288600000,1785297600000],[1785301200000,1785312000000]],"volumeRatio":1.142404,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09688","defaultTab":"news","newsList":[{"id":"2655832649","title":"【券商聚焦】国泰海通证券：全球多肽CDMO进入产能扩张周期","url":"https://stock-news.laohu8.com/highlight/detail?id=2655832649","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655832649?lang=zh_cn&edition=full","pubTime":"2026-07-29 09:21","pubTimestamp":1785288070,"startTime":"0","endTime":"0","summary":"国内外的多肽CDMO公司均加大对于产能的投资建设，尤其注重从临床前到商业化生产的一站式服务能力建设。2026年4月，凯莱英医药与天津经开区管委会签署合作备忘录，在天津经开区持续扩建化学大分子创新药CDMO研发生产基地，预计投资规模达20亿元人民币。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/MWIyNWQwZjQ4NTQyNjI4OTI5NDE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWIyNWQwZjQ4NTQyNjI4OTI5NDE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986985","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KURE","BK1564","01801","01177","LU1328277881.USD","LU1719994722.HKD","HK0000165453.HKD","LU0634319403.HKD","LU2242644610.SGD","IE00B5MMRT66.SGD","01877","LU1720050803.USD","06185","06160","LU0052750758.USD","LU0979878070.USD","LU0359202008.SGD","LU0051755006.USD","LU0417516738.SGD","BK1141","BK1588","09995","02616","IE00B0JY6N72.USD","BK1574","SG9999002463.SGD","LU1008478684.HKD","02611","IE00B543WZ88.USD","02142","601211","LU2476274308.USD","LU0307460666.USD","LU0561508036.HKD","BK1147","LU0181495838.USD","CDMO","161027","01093","LU0588546209.SGD","LU1251922891.USD","BK1583","02269","LU0348784397.USD","09688","09926","BK1610","LU0067412154.USD","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177071410","title":"美股异动｜中概股多数走低，文远知行跌4%，小马智行、再鼎医药、名创优品跌2%","url":"https://stock-news.laohu8.com/highlight/detail?id=1177071410","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177071410?lang=zh_cn&edition=full","pubTime":"2026-07-24 21:37","pubTimestamp":1784900227,"startTime":"0","endTime":"0","summary":"中概股多数走低， $纳斯达克中国金龙指数(HXC)$ 跌 0.48%，成分股文远知行跌 4%，小马智行、再鼎医药、名创优品跌 2%","market":"us","thumbnail":"https://static.tigerbbs.com/b823fa6c7d674b719a54def9b76b7c88","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/b823fa6c7d674b719a54def9b76b7c88"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WRD","09688","PONX","PONY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118081196","title":"再鼎医药(09688)拟于2026年8月6日披露截至6月30日未经审计中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1118081196","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118081196?lang=zh_cn&edition=full","pubTime":"2026-07-24 16:36","pubTimestamp":1784882170,"startTime":"0","endTime":"0","summary":"再鼎医药有限公司7月24日公告称，其董事会审计委员会将于2026年8月6日审议并批准公司及附属公司依据美国公认会计准则编制、截至2026年6月30日止三个月及六个月的未经审计中期业绩。此外，公司将不迟于2026年8月31日根据香港上市规则进一步发布截至2026年6月30日止六个月的中期业绩公告，除香港上市规则要求的附加资料及从美国公认会计准则至国际财务报告准则的对账外，相关财务数据预计与本次公布的中期业绩保持一致。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134444048","title":"异动解读｜再鼎医药盘中下跌5.05%，生物科技板块承压叠加大行下调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1134444048","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134444048?lang=zh_cn&edition=full","pubTime":"2026-07-24 14:52","pubTimestamp":1784875929,"startTime":"0","endTime":"0","summary":"7月24日，再鼎医药盘中下跌5.05%，报15.22港元/股，成交额5268.82万港元。消息面上，近日摩根大通将再鼎医药目标价从39美元大幅下调至32美元，叠加此前摩根士丹利下调港股目标价至19港元、中银国际下调至17港元，多家大行集体调降预期持续压制市场情绪。当日生物科技板块整体承压，康方生物跌4.04%、三生制药跌2.62%、信达生物跌2.53%，行业弱势进一步放大个股跌幅。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152087106","title":"异动解读｜再鼎医药盘中下跌5.05%，报15.33港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1152087106","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152087106?lang=zh_cn&edition=full","pubTime":"2026-07-17 10:52","pubTimestamp":1784256723,"startTime":"0","endTime":"0","summary":"7月17日，再鼎医药盘中下跌5.05%，报15.33港元/股，成交额4814.93万港元。再鼎医药所在的生物科技行业中，个股普遍走弱，康方生物跌12.08%，信达生物跌5.73%，三生制药跌11.73%，科伦博泰生物跌6.26%，百济神州跌2.78%。再鼎医药有限公司是一家主要从事生物制药业务的控股公司，致力于通过产品的发现、开发和商业化解决肿瘤、免疫、神经科学和感染性疾病领域未被满足的医疗需求，拥有从发现阶段到临床项目后期的一系列专利候选药物。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651341039","title":"创新药连续大涨，这次真的不一样了吗？","url":"https://stock-news.laohu8.com/highlight/detail?id=2651341039","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651341039?lang=zh_cn&edition=full","pubTime":"2026-07-16 17:05","pubTimestamp":1784192720,"startTime":"0","endTime":"0","summary":"政策上，医保初审通过率创新高，定价机制优化，并建立“医保+商保”双层支付体系；产业上，上半年BD交易总额达1100亿美元，国际竞争力显著提升；资金面上，内外资持续回流。行业正从“讲故事”转向盈利兑现，国金证券认为，2027年有望成为中国创新药海外商业化集中兑现的重要节点。","market":"hk","thumbnail":"https://static.tigerbbs.com/8daedf52c02cecfd417dcbd813afb3fa","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/8daedf52c02cecfd417dcbd813afb3fa"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3777107","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06622","159992","MEDX","09688","02268","03759","BK1161","09606","02137","03347","09966","02269","06978","BK1574","IBBQ","01672","00241","06606","09995","06996","02359","06618","01801"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1187091305","title":"异动解读｜再鼎医药盘中上涨5.05%，报16.22港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1187091305","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187091305?lang=zh_cn&edition=full","pubTime":"2026-07-16 09:55","pubTimestamp":1784166921,"startTime":"0","endTime":"0","summary":"7月16日，再鼎医药盘中上涨5.05%，报16.22港元/股，成交额5045.95万港元。再鼎医药所在的生物科技行业中，个股表现分化，信达生物跌2.11%，百济神州涨0.48%，康方生物跌0.48%，三生制药跌1.05%，映恩生物-B涨1.02%。再鼎医药有限公司是一家主要从事生物制药业务的控股公司，致力于通过产品的发现、开发和商业化解决肿瘤、免疫、神经科学和感染性疾病领域未被满足的医疗需求，拥有从发现阶段到临床项目后期的一系列专利候选药物。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115883589","title":"异动解读｜再鼎医药盘中下跌5.29%，报15.1港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1115883589","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115883589?lang=zh_cn&edition=full","pubTime":"2026-07-14 09:37","pubTimestamp":1783993068,"startTime":"0","endTime":"0","summary":"7月14日，再鼎医药盘中下跌5.29%，报15.1港元/股，成交额1097.69万港元。再鼎医药所在的生物科技行业中，个股表现分化，百济神州跌1.07%，信达生物涨1.01%，科伦博泰生物跌1.79%，三生制药跌4.37%，康方生物涨0.05%。再鼎医药有限公司是一家主要从事生物制药业务的控股公司，致力于通过产品的发现、开发和商业化解决肿瘤、免疫、神经科学和感染性疾病领域未被满足的医疗需求。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651991128","title":"【券商聚焦】中信证券：新基药目录有望加速创新药基层落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2651991128","media":"金吾财讯","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651991128?lang=zh_cn&edition=full","pubTime":"2026-07-14 08:57","pubTimestamp":1783990650,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券研究指，《2026年版国家基本药物目录》于7月9日正式发布，将于9月1日起实施。该机构认为，本次新版基药目录新增药物均已属于医保药品，随着基药与医保的深度协同联动，有望极大加速创新药的基层落地，医保控费与创新回报形成良性循环。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250106/ZGNkM2E3NDVjMTk0N2Q5ZDk4NjYxNjc1YjA4NjMzOTA5MjkwMDE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZGNkM2E3NDVjMTk0N2Q5ZDk4NjYxNjc1YjA4NjMzOTA5MjkwMDE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985769","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU0417516902.SGD","HK0000165453.HKD","KURE","06185","09926","600030","02142","09995","IBBQ","01177","159992","LU0314109678.HKD","LU1226288253.USD","LU1152091168.USD","BK1500","IE0008368742.USD","LU1997244956.HKD","LU0043850808.USD","06978","LU1328277881.USD","LU1226287792.SGD","LU0572944931.SGD","06030","IE00BPRC5H50.USD","09688","LU0405327494.USD","06160","LU1242518931.SGD","01877","02616","LU1960683339.HKD","LU1961090484.USD","LU0359201612.USD","01801","KCE","02269","LU0051755006.USD","LU2476274720.SGD","MEDX","LU2328871848.SGD","SG9999002463.SGD","LU2039709279.SGD","01093","LU0327786744.USD","BK1610","LU0823426480.USD","LU0588546209.SGD","LU0979878070.USD","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651568164","title":"【券商聚焦】中信建投：创新药企仍是高增长主线、BD交易持续催化业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2651568164","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651568164?lang=zh_cn&edition=full","pubTime":"2026-07-13 08:53","pubTimestamp":1783903985,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指出，1）制药产业链：创新药企仍是高增长主线，BD交易持续催化业绩。BD授权收入成为多家公司中期业绩关键变量。上游供应链受益于国产替代及下游需求恢复，Q2增速普遍提升，利润端弹性显著。建议关注Q2高增长公司的配置机会。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/NWI3NDNkNGUxZmM1MTMzOTE0MzEwMTk=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NWI3NDNkNGUxZmM1MTMzOTE0MzEwMTk=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985645","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185","LU0456846285.SGD","LU1993786604.SGD","601066","LU0516422366.SGD","01093","LU0348735423.USD","LU0348784397.USD","LU2488822045.USD","IE0008368742.USD","01177","KCE","IBBQ","IE00B5MMRT66.SGD","LU2097828474.EUR","LU1960683339.HKD","LU0067412154.USD","LU0501845795.SGD","BD","KURE","159992","06160","LU1813983027.USD","09688","LU1969619763.USD","LU1688375341.USD","06978","LU0455707207.USD","01877","02269","02142","LU0051755006.USD","LU0348825331.USD","LU0359201612.USD","IE00B0JY6N72.USD","LU1807302812.USD","LU1226288170.HKD","LU2242644610.SGD","01801","BK1588","BK1161","02616","BK1515","LU2097828631.EUR","MEDX","LU0359202008.SGD","09995","IE0008369823.USD","LU1961090484.USD","09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125623054","title":"异动解读｜再鼎医药盘中上涨5.15%，医保政策利好驱动创新药板块走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1125623054","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125623054?lang=zh_cn&edition=full","pubTime":"2026-07-10 13:21","pubTimestamp":1783660916,"startTime":"0","endTime":"0","summary":"7月10日，再鼎医药盘中上涨5.15%，报16.13港元，成交额1.58亿港元。消息面上，国家医保局近日表示医保目录新增谈判药品已配备至全国31万家定点医药机构，1200余万人次用上新增品种，商保创新药目录药品覆盖超1486家机构。此外，再鼎医药产品此前已现身医保药品目录初审名单。政策端支付环境持续优化，叠加创新药板块整体走强，生物科技板块内三生制药涨6.29%、信达生物涨4.46%、康方生物涨3.7%，板块联动效应明显。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177850654","title":"再鼎医药更新2026年6月股份变动月报，新增3,700,000股后总股本达1,137,828,030股","url":"https://stock-news.laohu8.com/highlight/detail?id=1177850654","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177850654?lang=zh_cn&edition=full","pubTime":"2026-07-07 18:29","pubTimestamp":1783420148,"startTime":"0","endTime":"0","summary":"再鼎医药有限公司于2026年7月7日发布2026年6月的股份变动月报，披露公司当月股本及相关证券发行的最新情况。报告期内，公司法定/注册股本维持在5,000,000,000股普通股不变，每股面值0.000006美元，总计约30,000美元。月末已发行普通股由上月底的1,134,128,030股增加3,700,000股至1,137,828,030股，库藏股数为零，尚有445,618,430股普通股以美国存托股份形式持有。报告期内，公司未发生任何股份回购及注销活动。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648547556","title":"再鼎医药(09688.HK)授出部分购股权、受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2648547556","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648547556?lang=zh_cn&edition=full","pubTime":"2026-07-03 16:34","pubTimestamp":1783067673,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","09688","BK1588","BK1574","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648634520","title":"【券商聚焦】中信建投：看好相关创新药及制药企业医保准入与商保增量空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2648634520","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648634520?lang=zh_cn&edition=full","pubTime":"2026-07-03 08:36","pubTimestamp":1783038993,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投研究指，2026年6月29日，国家医保局公示通过2026年基本医保目录及商保创新药目录调整初步形式审查的药品名单及相关信息。叠加今年首次引入的“预申报”机制，本次结果充分体现了医保目录调整对创新药的持续倾斜，看好相关创新药及制药企业的医保准入与商保增量空间。","market":"nz","thumbnail":"https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985028","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1688375341.USD","06160","06978","IE0008369823.USD","LU1226287875.USD","LU0315179316.USD","01177","LU2097828631.EUR","01477","09926","06185","BK1589","01877","601066","LU0456846285.SGD","LU0516422366.SGD","LU0348766576.USD","01801","LU0417516902.SGD","09995","LU2039709279.SGD","LU0043850808.USD","LU3063872942.SGD","SG9999004220.SGD","LU2488822045.USD","IE00B031HY20.USD","IE00B5MMRT66.SGD","HK0000165453.HKD","LU2097828714.EUR","LU0072913022.USD","LU1961090484.USD","02142","LU0067412154.USD","LU2097828805.USD","LU2476274308.USD","LU2476274720.SGD","02269","LU0501845795.SGD","09688","LU0979878070.USD","159992","01093","LU0502904849.HKD","LU1226287792.SGD","LU1969619763.USD","LU0856984785.SGD","02616","LU2778985437.USD","LU1242518931.SGD","LU0417516738.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133860548","title":"富时中国A50指数期货跌逾3%，热门中概股夜盘普跌、金山云夜盘跌逾6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1133860548","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133860548?lang=zh_cn&edition=full","pubTime":"2026-06-26 11:47","pubTimestamp":1782445648,"startTime":"0","endTime":"0","summary":"富时中国A50指数期货持续走低，跌幅扩大至逾3%。热门中概股夜盘普跌，金山云夜盘跌逾6%，再鼎医药跌5%，贝壳跌4%。","market":"hk","thumbnail":"https://static.tigerbbs.com/342bdaa24f11a7e9af00a6ff6b22a4db","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/342bdaa24f11a7e9af00a6ff6b22a4db"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KC","09688","CNmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147830928","title":"异动解读｜再鼎医药盘中下跌5.04%，生物科技板块集体走弱叠加合作方临床失败余波持续","url":"https://stock-news.laohu8.com/highlight/detail?id=1147830928","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147830928?lang=zh_cn&edition=full","pubTime":"2026-06-26 11:28","pubTimestamp":1782444499,"startTime":"0","endTime":"0","summary":"6月26日，再鼎医药盘中下跌5.04%，报13.74港元，成交额9530.75万港元。此外，合作方Novocure于6月18日宣布肿瘤电场疗法TTFields治疗胶质母细胞瘤三期临床TRIDENT未达OS主要终点，HR=0.953，p值0.519，Novocure当日暴跌20%。再鼎医药拥有TTFields大中华区权益，该产品以OPTUNE品牌在国内销售，临床失败对其管线价值的负面影响仍在消化中。叠加近期公司披露Form 144拟议出售证券文件，市场情绪进一步承压。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646840322","title":"【券商聚焦】中信证券：中国创新药BD交易金额超预期增长 即将进入密集数据催化期","url":"https://stock-news.laohu8.com/highlight/detail?id=2646840322","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646840322?lang=zh_cn&edition=full","pubTime":"2026-06-25 09:03","pubTimestamp":1782349398,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券研报指，2026年以来，中国创新药BD交易金额超预期增长，产业全球竞争力进一步提升；国内市场快速放量，从2025年报来看，头部创新药企业在新产品驱动下，创新药收入快速增长，Biopharma陆续进入盈利拐点。研报认为创新药产业全球价值凸显，接下来将进入密集数据催化期。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250109/NjdhYmE3ZDczMTc4NjgyMDYzMDA3NjI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NjdhYmE3ZDczMTc4NjgyMDYzMDA3NjI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984448","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688","BK0196","LU1064130708.USD","LU1226288253.USD","01801","IE00B031HY20.USD","BD","06978","LU0348767384.USD","LU1328277881.USD","LU2097828474.EUR","LU0181495838.USD","LU1242518857.USD","06185","BK1574","LU0856984785.SGD","SG9999002562.SGD","LU0501845795.SGD","LU0405327148.USD","LU1794554557.SGD","02269","09926","LU2289578879.USD","IE00B0JY6N72.USD","LU1813983027.USD","LU2039709279.SGD","06160","LU1997245094.SGD","01877","BK0028","09995","01177","159992","LU2328871848.SGD","600030","02142","IE00BZ08YT58.USD","SG9999004220.SGD","LU0327786744.USD","IE0008368742.USD","06030","LU1960683339.HKD","LU0359202008.SGD","01093","IE00B5MMRT66.SGD","SG9999002463.SGD","02616","LU0823426480.USD","BK1610","LU0540923850.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645001206","title":"医药板块逆市走高 山东新华制药(00719)涨23.59%、康诺亚-B(02162)涨5.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645001206","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645001206?lang=zh_cn&edition=full","pubTime":"2026-06-23 10:08","pubTimestamp":1782180500,"startTime":"0","endTime":"0","summary":"市场交易结构出现变化，医药与科技板块不再呈现明显跷跷板效应，医疗服务、CXO赛道带动板块韧性修复。临近二季度末，市场开始提前交易行业业绩预期，资金重点布局两大主线，分别为商业化放量提速的创新药标的，以及受益于投融资回暖的CXO、生命科学上游龙头。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250110/NmI5OTlmYjAxY2FmOGFlNWZkYjg2NDM0MTE4MzUwMDcw.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/NmI5OTlmYjAxY2FmOGFlNWZkYjg2NDM0MTE4MzUwMDcw.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984274","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BPRC5H50.USD","159938","LU0516423091.SGD","IE00B0JY6N72.USD","09969","06990","02268","06160","LU0359202008.SGD","LU0348783233.USD","LU1303224171.USD","LU0856984785.SGD","09926","LU0326950275.SGD","LU0307460666.USD","LU0140636845.USD","LU0456846285.SGD","LU3063872942.SGD","SG9999002562.SGD","LU0052750758.USD","LU0516422952.EUR","IE00B5MMRT66.SGD","LU0979878070.USD","LU0417516902.SGD","LU0588546209.SGD","LU0039217434.USD","01877","LU2328871848.SGD","BK1589","LU2039709279.SGD","LU0320764599.SGD","LU0456827905.SGD","BK1583","LU0516422366.SGD","BK1576","09688","LU0359201612.USD","LU0327786744.USD","BK1161","02162","00719","09939","LU1880383366.USD","LU1720050803.USD","02269","BK1191","LU1251922891.USD","LU1242518857.USD","LU0051755006.USD","09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141508440","title":"异动解读｜再鼎医药盘中上涨5.46%，生物科技板块集体走强叠加前日超跌回补","url":"https://stock-news.laohu8.com/highlight/detail?id=1141508440","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141508440?lang=zh_cn&edition=full","pubTime":"2026-06-23 09:52","pubTimestamp":1782179525,"startTime":"0","endTime":"0","summary":"6月23日，再鼎医药盘中上涨5.46%，报14.62港元，成交额2936.47万港元。消息面上，生物科技板块今日集体走强，康方生物涨6.33%、荣昌生物涨5.39%、信达生物涨4.25%、百济神州涨4.03%，板块联动效应显著。此前6月22日，再鼎医药因合作方Novocure肿瘤电场疗法TTFields治疗胶质母细胞瘤三期临床TRIDENT未达OS主要终点而大跌逾5%，今日涨幅带有超跌回补特征。此外，公司近日披露股权激励计划下发行370万股普通股，属常规激励安排。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101257704","title":"再鼎医药：6月22日发行3,700,000股普通股，已发行股本变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1101257704","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101257704?lang=zh_cn&edition=full","pubTime":"2026-06-22 20:46","pubTimestamp":1782132368,"startTime":"0","endTime":"0","summary":"再鼎医药有限公司于2026年6月22日发布公告，披露已根据2015、2017、2022及2024年股权激励计划向董事及其他参与人发行新股，导致公司已发行股本变动。本次发行分为两部分：其一，向董事以外参与人发行1,031,840股普通股，约占原已发行股本总数的0.11%，每股发行价为0港元；其二，向公司董事发行2,668,160股普通股，约占原已发行股本总数的0.42%，每股发行价同样为0港元。发行完成后，公司已发行股本增至1,137,828,030股，库藏股数量仍为0股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"再鼎医药：6月22日发行3,700,000股普通股，已发行股本变动","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.zailaboratory.com","stockEarnings":[{"period":"1week","weight":-0.1067},{"period":"1month","weight":0.0134},{"period":"3month","weight":-0.1257},{"period":"6month","weight":0.0967},{"period":"1year","weight":-0.5521},{"period":"ytd","weight":0.0549}],"compareEarnings":[{"period":"1week","weight":0.0368},{"period":"1month","weight":0.1208},{"period":"3month","weight":0.0012},{"period":"6month","weight":-0.0577},{"period":"1year","weight":0.0111},{"period":"ytd","weight":0.0069}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"再鼎医药有限公司是一家主要从事生物制药业务的控股公司。该公司致力于通过产品的发现、开发和商业化解决肿瘤、免疫、神经科学和感染性疾病领域未被满足的医疗需求。该公司拥有从发现阶段到临床项目后期的一系列专利候选药物，其中包括“则乐”、“OPTUNE”、“擎乐”、“纽再乐”及“卫伟迦”等。该公司在国内市场和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.017355},{"month":2,"riseRate":0.666667,"avgChangeRate":0.068855},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.098942},{"month":4,"riseRate":0.666667,"avgChangeRate":0.061043},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.046017},{"month":6,"riseRate":0.5,"avgChangeRate":-0.004904},{"month":7,"riseRate":0.666667,"avgChangeRate":0.054101},{"month":8,"riseRate":0.6,"avgChangeRate":-0.021717},{"month":9,"riseRate":0.4,"avgChangeRate":-0.054178},{"month":10,"riseRate":0.5,"avgChangeRate":-0.051338},{"month":11,"riseRate":0.5,"avgChangeRate":0.047251},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.024481}],"exchange":"SEHK","name":"再鼎医药","nameEN":"ZAI LAB"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"再鼎医药(09688)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供再鼎医药(09688)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"再鼎医药,09688,再鼎医药股票,再鼎医药股票老虎,再鼎医药股票老虎国际,再鼎医药行情,再鼎医药股票行情,再鼎医药股价,再鼎医药股市,再鼎医药股票价格,再鼎医药股票交易,再鼎医药股票购买,再鼎医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"再鼎医药(09688)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供再鼎医药(09688)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}